RU2431663C2 - IMMUNOBIOLOGICAL ANTIALLERGIC AGENT (VERSIONS) AND Lactobacillus acidophilus 100 "аш" PA STRAIN USED FOR PRODUCTION OF IMMUNOBIOLOGICAL ANTIALLERGIC AGENT - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: according to the invention, versions of an immunobiological antiallergic agent contain Lactobacillus acidophilus 100 "аш" PA strain, collection No. 207, is stored in the State collection of microorganisms of normal microflora Federal State Research Institution Gabrichevskiy Moscow Research Institution of Epidemiology and Microbiology of Federal Service for Supervision of Consumer Rights and Human Welfare in a culture medium in amount 10⁶-10¹⁰ CFU/ml. The immunobiological antiallergic agent additionally contains species-specific virulent bacteriophages and bacteriophages with induced virulence, a biomass of Lactobacillus acidophilus "КзШз4" strain in a culture medium in amount 10⁶-10¹⁰ CFU/ml, a biomass of Lactobacillus acidophilus NKi strain in the culture medium in amount 10⁶-10¹⁰ CFU/ml and a biomass of Bifidobacterium bacteria in the culture medium in amount 106-1010 CFU/ml. The immunobiological antiallergic agent additionally contains target additives in amount 0.01-95.0 wt % from mass of the agent. The additives are selected from a number of: glycine, cysteine, copper sulphate, copper gluconate, quinosol, chitosan, licorice root extract, hips extract, origanum extract, cranberry extract and a flavouring agent. The immunobiological antiallergic agent is presented in the form of a suspension. The Lactobacillus acidophilus 100 "аш" PA strain is produced by means of a sequence of multiple passages through a nutrient medium MPC with added sources of histamine, Cu¹⁺, Cu²⁺, Co²⁺, Ni²⁺ ions and at culture pH 6.2-7.4. The agent is used for prevention and treatment of allergic or pseudo-allergic disease without an accompanying pathology or in a combination with an infectious disease, intestinal dysbacteriosis and psychological adaptation disorders.

EFFECT: more efficient antiallergic action of the immunobiological agent on the basis of lactobacilli.

10 cl, 3 tbl

Description

The invention relates to medicine and the pharmaceutical industry and can be used in the production and use of medical immunobiological preparations and biologically active food additives.

The anti-allergic effect of lactic acid bacteria, mainly lactobacilli, is known (Weid T., Ibnou-Zekri N., Pfeifer A. Novel probiotics for the management of allergic inflammation // Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. - 2002. - Vol. 34, No. 2. - P.25-28), which is due to a decrease in the level of specific IgE in serum (Peng S., Lin JY, Lin MY Antiallergic effect of milk fermented with lactic acid bacteria in a murine animal model // Journal of agricultural and food chemistry. - 2007. - Vol. 55, No. 13. - P.5092-5096) when stimulated by lactobacilli synthesis of regulatory cytokines: strains of Lactobacillus plantarum CCRC 12944, Lactobacillus acidophilus CCRC 14079, Lactobacillus rhamnosus CCRC 10940, Lactobacillus paracasei subsp.paracasei CCRC 14023, Lactobacillus delbrueckii subsp.bulgaricus CCRC 12297, Lactobacillus delbrueckii subsp.bulgaricus CCLP-140 0047849 A1, C12N 1/20); strain Lactobacillus paracasei KW 3110 stimulated lymphocyte synthesis of interleukin-12 and interleukin-4 (EP patent 1634600 Al, A61K 35/74, A61P 11/02, 11/06, 17/00, 27/02, 37/08, A23L 1 / 30, C12N 1/20); synthesis of interferon-γ by splenocytes and peripheral blood mononuclear cells stimulated the strain Lactobacillus paracasei GM-080 (US patent, publication number 2005/0214271 A1; US patent 6994848 B2, A61K 45/00, C12N 1/20).

However, strains of different types of lactobacilli, for example: Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacillus delbrueckii, are capable of producing histamine (Garai G., Dueñas MT, Irastorza A., Moreno-Arribas MV Biogenic amine production by lactic acid bacteria isolated from cider // in applied microbiology. - 2007. - Vol. 45, No. 5. - P.473-478; Azcarate-Peril MA, Altermann E., Hoover-Fitzula RL, Cano RJ, Klaenhammer TR Identification and inactivation of genetic loci involved with Lactobacillus acidophilus acid tolerance // Applied and environmental microbiology. - 2004.-Vol. 70, No. 9. - P.5315-5322; Leuschner RG, Kurihara R, Hammes WP. Effect of enhanced proteolysis on formation of biogenic amines by lactobacilli during Gouda cheese ripening // International journal of food microbiology. - 1998. - Vol.20, No. 44. - P.15-20). This drawback limits the indications for the use of agents containing lactobacilli and prevents the use of lactobacilli as ingredients in compositions that are promising for the prevention and treatment of diseases in the development of which the level of histamine in the body matters.

Known immunobiological agents and starter cultures of acidophilic cultures based on a strain of Lactobacillus acidophilus 100 al, which are the closest analogues of the claimed immunobiological agent (SU patent 1004471, A23C 9/123, C12N 1/20; Voroshilina NN, Microbes of the species Lactobacillus acidophilus as the basis for pharmacopeia forms of bacterial preparations. Abstract of dissertation for the degree of candidate of medical sciences. - Moscow, 1982. - 22 pp.).

The strain Lactobacillus acidophilus 100 ash was isolated from the feces of a healthy adult, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medical Sciences named after G.N. Gabrichevsky Rospotrebnadzor under No. 118 and is characterized by the following characteristics.

1. Cultural and morphological properties.

Fixed gram-positive, direct, indisputable sticks, located singly or in the form of chains of 2-4 or more cells.

When grown on agar with hydrolyzed milk, the strains form dark curly colonies on the surface and in the form of “spiders” in depth. The diameter of the colonies is 1-2 mm.

2. Enzymatic activity.

The strain is homoenzymatic. Catalase does not produce, gelatin does not thin. It ferments without the formation of gas glucose, lactose, maltose, galactose, sucrose. Fermenting milk when making 1-3% sourdough for 6-7 hours, reduces the pH of milk to 3.8-4.2 in 10-12 hours. The proteolytic activity of 58.8 mg% in the sum of three amino acids in terms of tyrosine.

3. Antagonistic properties.

Antagonistically active against test cultures: Shigella flexneri - 2 strains, Shigella sonnei, enteropathogenic Escherichia coli, Staphylococcus aureus, Proteus vulgaris, Proteus mirabilis. Zone of growth inhibition of test strains of at least 20 mm.

4. Resistance to antibiotics. Resistant to monomycin, neomycin, kanamycin, polymyxin, penicillin, erythromycin, streptomycin, tetracycline.

The disadvantage of this strain is that it does not have a stable anti-allergic effect in humans.

The objective of the invention is to obtain variants of an immunobiological agent containing a strain of Lactobacillus acidophilus 100 al PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Medical Research Institute named after G.N.Gabrichevsky Rospotrebnadzor under No. 207, exhibiting antiallergic effect in all patients, and the basis of the claimed immunobiological agent is strain Lactobacillus acidophilus 100 ash PA, exhibiting anti-allergic effect in all patients.

The strain Lactobacillus acidophilus 100 ash PA was obtained from the collection strain of Lactobacillus acidophilus 100 ash by successive multiple passages through the medium of MPC with the addition of sources of histamine, Cu ¹⁺ , Cu ²⁺ , Co ²⁺ , Ni ^{2+ ions} and at a culture pH of 6.2 -7.4 and selection of clones that do not increase the histamine content in the culture medium, which ensured the presence and stabilization of the sign of antiallergic action in humans of variants of the claimed immunobiological agent.

The strain Lactobacillus acidophilus 100 al PA is deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medical Sciences named after G.N.Gabrichevsky of Rospotrebnadzor under No. 207 and is characterized by the following properties.

1. Cultural and morphological properties.

Fixed gram-positive, direct, indisputable sticks, located singly or in the form of chains of 2-4 or more cells.

When grown on agar with hydrolyzed milk, the strains form dark curly colonies on the surface and in the form of “spiders” in depth. The diameter of the colonies is 1-2 mm.

2. Enzymatic activity.

The strain is homoenzymatic. Catalase does not produce, gelatin does not thin. It ferments without the formation of gas glucose, lactose, maltose, galactose, sucrose. Fermenting milk when making 1-3% sourdough for 6-7 hours, reduces the pH of milk to 3.8-4.2 in 10-12 hours. The proteolytic activity of 58.8 mg% in the sum of three amino acids in terms of tyrosine.

3. Antagonistic properties.

Antagonistically active against test cultures: Shigella flex-neri - 2 strains, Shigella sonnei, enteropathogenic Escherichia coli, Staphylococcus aureus, Proteus vulgaris, Proteus mirabilis. Zone of growth inhibition of test strains of at least 20 mm.

4. Resistance to antibiotics. Resistant to monomycin, neomycin, kanamycin, polymyxin, penicillin, erythromycin, streptomycin, tetracycline.

5. Biological properties.

When taking an immunobiological agent - a strain of Lactobacillus acidophilus 100 ash PA in 34 patients, in all cases there were established clinical criteria for the antiallergic effect of the immunobiological agent, namely a reduction in the clinical symptoms of allergy after oral administration 1-2 times a day, for 5-10 days, 5 doses of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis.

Variants of an immunobiological antiallergic agent contain a strain of Lactobacillus acidophilus 100 al PA in the culture medium in an amount of 10 ⁶ -10 ¹⁰ CFU / ml and may contain any known target additives in the ratio usually used to obtain biomass of bacterial strains of normoflora, suspensions containing strains of bacteria of normoflora. The inventive tool may contain species-specific bacteriophages with lytic activity not less than 10 ^-4 according to Appelman in relation to test strains and bacterial isolates isolated from the human body in the filtrate of a concentrate of phagolysate of non-isogenic bacteria, biomass of the strain Lactobacillus acidophilus K ₃ Ш ₂₄ in the culture medium in an amount of 10 ⁶ -10 ¹⁰ CFU / ml, the biomass of the strain Lactobacillus acidophilus NK ₁ in the culture medium in the amount of 10 ⁶ -10 ¹⁰ CFU / ml and the biomass of bacteria of the genus Bifidobacterium in the culture medium in the amount of 10 ⁶ -10 ¹⁰ CFU / ml. The inventive tool may contain species-specific virulent bacteriophages and bacteriophages with induced virulence, selected from the following: staphylococcal bacteriophage, streptococcal bacteriophage, coli bacteriophage, Proteus bacteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, bacterial bacteriophage, bacterial bacteriophage, bacterial bacteriophage, bacterial bacteriophage, shigellosis bacteriophage, bacterial bacteriophage, bacterial bacteriophage, and shigellosis bacteriophage bacteriophage. The inventive tool may contain bacteria of the genus Bifidobacterium selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bumidum 791, Bifidobacterium breve 79-88, Bifidobacterium bumidium infantis 79-43, Bifidobacterium biumidium infantis 79-43, Bifidobacterium biumidium longis 79-43, 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3, and Bifidobacterium adolescentis G7513. The inventive tool may additionally contain target additives in an amount of 0.01-95.0 wt.% By weight of the agent selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, licorice root extract, rosehip extract, oregano extract , cranberry extract and flavoring supplement - and be presented as a suspension. The inventive tool can be used in the prevention and treatment of allergic or pseudo-allergic diseases without associated pathology or in combination with an infectious disease, intestinal dysbiosis and a disorder of psychological adaptation.

Examples of the presence of anti-allergic effects in patients when taking variants of an immunobiological agent containing the Lactobacillus acidophilus 100 al.

Example 1. Patient A., 38 years old. Diagnosis: allergic urticaria. In the treatment of the patient, an immunobiological anti-allergic agent was used - the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Medicine named after G.N. Gabrichevsky of the Federal Service for Supervision of Human Welfare, No. 207, which was administered orally 2 times a day for 5 days at 5 doses (5 × 10 ⁷ CFU) Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, the clinical signs of the disease resolved. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent, the strain Lactobacillus acidophilus 100 al PA, was established.

Example 2. Patient S., 40 years old. Diagnosis: allergic dermatitis caused by food eaten. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml, which was prescribed orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, the clinical signs of the disease resolved. Therefore, the presence of an antiallergic effect of an immunobiological antiallergic agent containing a strain of Lactobacillus acidophilus 100 al PA was established.

Example 3. Patient K., 36 years old. Diagnosis: allergic gastroenteritis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ⁷ CFU / ml, which was prescribed orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, the clinical signs of the disease resolved. Therefore, the presence of an antiallergic effect of an immunobiological antiallergic agent containing a strain of Lactobacillus acidophilus 100 al PA was established.

Example 4. Patient B., 28 years old. Diagnosis: allergic dermatitis caused by food eaten. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ¹⁰ CFU / ml, which was prescribed orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, the clinical signs of the disease resolved. Therefore, the presence of an antiallergic effect of an immunobiological antiallergic agent containing a strain of Lactobacillus acidophilus 100 al PA was established.

Example 5. Patient S., 30 years old. Diagnosis: acute urticaria (pseudo-allergic), chronic tonsillitis in the acute stage, carriage of Staphylococcus aureus. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml and containing filtrate the phagolysate of non-isogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteinaceous bacteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages and bacteriophages with induced virulence with lytic activity not lower than 10 ^-4 according to Appelman, isolate bacteria from test strains from concentrate the filtrate fagolizata nelizogennyh bacteria, which was orally administered 1 time per day for 6 days for 5 doses (5 × ¹⁰ July CFU) Lactobacillus acidophilus PA 100 Al - the maximum one-quarter times the dose used in the bowel dysbacteriosis. After the course of treatment, allergic urticaria resolved, Staphylococcus aureus was eliminated, exacerbation of chronic tonsillitis stopped within 3 days (previous exacerbations of chronic tonsillitis in the patient lasted for 7-10 days). Therefore, the presence of anti-allergic action and anti-infectious action of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA was established.

Example 6. Patient L., 29 years old. Diagnosis: allergic urticaria, acute tonsillitis in the acute stage, carriage of Streptococcus pyogenes. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ⁷ CFU / ml and containing filtrate the phagolysate of non-isogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteinaceous bacteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages and bacteriophages with induced virulence with lytic activity not lower than 10 ^-4 according to Appelman, isolate bacteria from test strains from concentrate the filtrate fagolizata nelizogennyh bacteria, which was orally administered 1 time per day for 6 days for 5 doses (5 × ¹⁰ July CFU) Lactobacillus acidophilus PA 100 Al - the maximum one-quarter times the dose used in the bowel dysbacteriosis. After the course of treatment, allergic urticaria resolved, Streptococcus pyogenes eliminated, exacerbation of chronic tonsillitis stopped within 4 days (previous exacerbations of chronic tonsillitis in the patient continued for 10-12 days). Therefore, the presence of anti-allergic action and anti-infectious action of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA was established.

Example 7. Patient R., 33 years old. Diagnosis: allergic dermatitis, chronic pharyngitis in the acute stage, carriage of Staphylococcus aureus. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ¹⁰ CFU / ml and containing filtrate the phagolysate of non-isogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteinaceous bacteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages with lytic activity not less than 10 ^-4 according to Appelman in relation to test strains and isolated from the human body isolates of non-bacterial bacterial isolate in the filtrate which was orally administered 1 time per day for 6 days for 5 doses (5 × ¹⁰ July CFU) Lactobacillus acidophilus PA 100 Al - the maximum single dose used in dysbacteriosis ki echnika. After the course of treatment, allergic dermatitis resolved, Staphylococcus aureus was eliminated, exacerbation of chronic pharyngitis stopped within 6 days (previous exacerbations of chronic tonsillitis in the patient lasted for 2-3 weeks). Therefore, the presence of anti-allergic action and anti-infectious action of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA was established.

Example 8. Patient S., 29 years old. Diagnosis: allergic urticaria and intestinal dysbiosis. The patient was treated with an immunobiological anti-allergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml and biomass Lactobacillus acidophilus K ₃ W ₂₄ in a culture medium in an amount of 10 ⁶ CFU / ml, which was administered orally 1 time per day, for 6 days, 5 doses (5 × 10 ⁷ CFU) Lactobacillus acidophilus 100 al PA - maximum single the dose used for intestinal dysbiosis. After the course of treatment, allergic urticaria was resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 9. Patient R., 37 years old. Diagnosis: allergic dermatitis and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁷ CFU / ml and biomass Lactobacillus acidophilus K ₃ W ₂₄ in the culture medium in an amount of 10 ⁷ CFU / ml, which was administered orally 1 time per day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - maximum single the dose used for intestinal dysbiosis. After the course of treatment, allergic dermatitis resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 10. Patient D., 30 years. Diagnosis: allergic gastroenteritis and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ¹⁰ CFU / ml and biomass Lactobacillus acidophilus K ₃ W ₂₄ in a culture medium in an amount of 10 ¹⁰ CFU / ml, which was administered orally 1 time per day, for 6 days, 5 doses (5 × 10 ⁷ CFU) Lactobacillus acidophilus 100 al PA - maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic gastroenteritis resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 11. Patient O., 40 years old. Diagnosis: allergic urticaria and intestinal dysbiosis. The patient was treated with an immunobiological anti-allergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml and biomass Lactobacillus acidophilus NK ₁ in the culture medium in an amount of 10 ⁶ CFU / ml, which was orally administered 1 time per day for 6 days for 5 doses (5 × ¹⁰ July CFU) Lactobacillus acidophilus PA 100 Al - the maximum single eskers, used for intestinal dysbiosis. After the course of treatment, allergic urticaria was resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 12. Patient S., 28 years old. Diagnosis: allergic dermatitis and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁷ CFU / ml and biomass Lactobacillus acidophilus NK ₁ in the culture medium in an amount of 10 ⁷ cfu / ml, which was orally administered 1 time per day for 6 days for 5 doses (5 × ¹⁰ July CFU) Lactobacillus acidophilus PA 100 Al - the maximum single eskers, used for intestinal dysbiosis. After the course of treatment, allergic dermatitis resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 13. Patient L., 25 years old. Diagnosis: allergic dermatitis and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ¹⁰ CFU / ml and biomass Lactobacillus acidophilus NK ₁ in a culture medium in an amount of 10 ¹⁰ CFU / ml, which was administered orally 1 time per day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - maximum single the dose used for intestinal dysbiosis. After the course of treatment, allergic gastroenteritis resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 14. Patient S., 41 years old. Diagnosis: allergic urticaria and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml and containing cultivation medium in an amount of 10 ⁶ CFU / ml biomass of bacteria of the genus Bifidobacterium (table 2), selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88, Bifidobacteriumium infantis longum I-3, Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513 - which was administered orally 1 time per day for 5 days at 5 doses ( 5x10 ⁷ CFU) Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic urticaria was resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 15. Patient Z., 38 years old. Diagnosis: pink lichen and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ⁷ CFU / ml and containing cultivation medium in an amount of 10 ⁷ CFU / ml biomass of bacteria of the genus Bifidobacterium (table 2), selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88, Bifidobacteriumium infantis longum I-3, Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513, which was administered orally 1 time per day, for 6 days, 5 times 5 × 10 ⁷ CFU) Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, pink lichen resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 16. Patient K., 26 years old. Diagnosis: allergic gastroenteritis and intestinal dysbiosis. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ¹⁰ CFU / ml and containing cultivation medium in an amount of 10 ¹⁰ CFU / ml biomass of bacteria of the genus Bifidobacterium (table 2), selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88, Bifidobacteriium infantis um longum I-3, Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513 - which was administered orally 1 time per day, for 6 days, 5 times (5 × 10 ⁷ CFU) Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic gastroenteritis resolved, and intestinal microbiocenosis was corrected. Therefore, the presence of the antiallergic effect of the immunobiological antiallergic agent containing the Lactobacillus acidophilus strain 100 ash PA and its effectiveness in intestinal dysbiosis were established.

Example 17. Patient S., 32 years old. Diagnosis: allergic gastroenteritis, chronic tonsillitis in the acute stage, intestinal dysbiosis, carriage of Staphylococcus aureus. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml, containing filtrate the phagolysate of non-lysogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteus b an acteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages and bacteriophages with induced virulence with lytic activity not lower than 10 ^-4 according to Appelman isolate from bacteria in the test strains and concentrate the filtrate fagolizata nelizogennyh bacterial biomass comprising Lactobacillus acidophilus strain K ₃ W ₂₄ in the culture medium in an amount June ¹⁰ cfu / ml and containing a cool environment tivirovaniya in an amount June ¹⁰ CFU / ml the biomass of bacteria of the genus Bifidobacterium (Table 2) selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88 , Bifidobacterium infantis 79-43, Bifidobacterium longum I-3 , Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513. An immunobiological agent was administered orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic gastroenteritis resolved, exacerbation of chronic tonsillitis stopped within 5 days (previous exacerbations of chronic tonsillitis in the patient lasted for 10-12 days). Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. Therefore, the presence of an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis were established.

Example 18. Patient S., 31 years old. Diagnosis: allergic urticaria, chronic pharyngitis in the acute stage, gastroenteritis of presumably infectious origin, intestinal dysbiosis, carriage of Staphylococcus aureus. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ⁷ CFU / ml, containing filtrate the phagolysate of non-lysogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteus b an acteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages and bacteriophages with induced virulence with lytic activity not lower than 10 ^-4 according to Appelman isolate from bacteria in the test strains and concentrate the filtrate fagolizata nelizogennyh bacterial biomass comprising Lactobacillus acidophilus strain K ₃ W ₂₄ in the culture medium in an amount of 10 ⁷ cfu / ml and containing a cool environment tivirovaniya in an amount of 10 ⁷ cfu / ml of bacteria biomass genus Bifidobacterium (Table 2) selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88 , Bifidobacterium infantis 79-43, Bifidobacterium longum I-3 , Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513. An immunobiological agent was administered orally once a day, for 6 days, 5 doses (5x10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic urticaria and gastroenteritis resolved, exacerbation of chronic pharyngitis stopped within 7 days (previous exacerbations of chronic pharyngitis in the patient lasted for 2-3 weeks). Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. Therefore, the presence of an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis were established.

Example 19. Patient B., 36 years old. Diagnosis: allergic rhinitis, chronic tonsillitis in the acute stage, intestinal dysbiosis, carriage Streptococcus pyogenes. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ¹⁰ CFU / ml, containing filtrate the phagolysate of non-isogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteinaceous akteriofag, Pseudomonas phage, Salmonella phage, shigellosis bacteriophage, and bacteriophage enterococcal klebsiellezny bacteriophage, - a virulent bacteriophages and bacteriophages with induced virulence with lytic activity of not lower than 10 ^-4 for Appelmanu against the test strains and isolated from the human body in the bacteria isolates concentrate the filtrate fagolizata nelizogennyh bacterial biomass comprising Lactobacillus acidophilus strain K ₃ W ₂₄ in the culture medium in an amount of 10 ¹⁰ pfu / ml and containing a medium ku tivirovaniya in an amount of 10 ¹⁰ pfu / ml of biomass of bacteria of Bifidobacterium (Table 2) selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88 , Bifidobacterium infantis 79-43, Bifidobacterium longum I-3 , Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513. An immunobiological agent was administered orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic rhinitis resolved, exacerbation of chronic tonsillitis stopped within 3 days (previous exacerbations of chronic tonsillitis in the patient lasted for 7-10 days). Correction of intestinal microbiocenosis occurred. Streptococcus pyogenes was eliminated. Therefore, the presence of an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis were established.

Example 20. Patient S., 28 years old. Diagnosis: allergic dermatitis caused by food eaten, allergic gastroenteritis, intestinal dysbiosis, carriage Staphylococcus aureus. The patient was treated with an immunobiological antiallergic agent, presented in the form of a suspension, containing the biomass of the strain Lactobacillus acidophilus 100 al PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Medical Institution named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ KOE / ml and containing target additives (table 3) in an amount of 0.01 wt.% by weight of a product selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, root extract with boats, rosehip extract, oregano, cranberry extract and flavors. An immunobiological agent was administered orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic dermatitis and allergic gastroenteritis resolved. Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. Therefore, the presence of an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis were established.

Example 21. Patient S., 30 years old. Diagnosis: allergic dermatitis caused by food eaten, allergic gastroenteritis, intestinal dysbiosis, Staphylococcus aureus carriage, a disorder of psychological adaptation. In the treatment of the patient, an immunobiological antiallergic agent was used, presented in the form of a suspension, containing the biomass of the strain Lactobacillus acidophilus 100 al PA, deposited in the State collection of microorganisms of normal microflora of G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a cultivation medium in an amount of 10 ⁷ CFU / ml and containing target additives (table 3) in an amount of 10.0 wt.% By weight of a product selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, licorice root extract, rosehip extract, oregano extract, cranberry extract and flavoring additive. An immunobiological agent was administered orally once a day, for 6 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic dermatitis and allergic gastroenteritis resolved. Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. A stable psycho-emotional state was restored (irritability, excitability decreased, emotional reactions became more balanced). Therefore, the presence of an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA was found, its effectiveness in intestinal dysbiosis and a disorder of psychological adaptation.

Example 22. Patient A., 32 years old. Diagnosis: allergic dermatitis, intestinal dysbiosis, Staphylococcus aureus carriage, a disorder of psychological adaptation. The patient was treated with an immunobiological antiallergic agent, presented in the form of a suspension, containing the biomass of the strain Lactobacillus acidophilus 100 al PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Pedagogical Institute named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a cultivation medium in the amount of ¹⁰ CFU / ml and containing target additives (table 3) in an amount of 95.0 wt.% by weight of a product selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, root extract with olodki, rosehip extract, oregano extract, cranberry extract and flavoring additive. An immunobiological agent was administered orally once a day, for 8 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, allergic dermatitis resolved. Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. A stable psycho-emotional state was restored (irritability, excitability decreased, emotional reactions became more balanced). Therefore, the presence of an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA was found, its effectiveness in intestinal dysbiosis and a disorder of psychological adaptation.

Example 23. Patient S., 42 years old. Diagnosis: pink lichen, chronic pharyngitis in the acute stage, intestinal dysbiosis, carriage Streptococcus pyogenes. The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in the amount of 10 ⁶ CFU / ml, containing filtrate the phagolysate of non-lysogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteus b an acteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages and bacteriophages with induced virulence with lytic activity not lower than 10 ^-4 according to Appelman isolate from bacteria in the test strains and concentrate the filtrate fagolizata nelizogennyh bacterial biomass comprising Lactobacillus acidophilus strain K ₃ W ₂₄ in the culture medium in an amount June ¹⁰ cfu / ml, in a cul medium comprising ivirovaniya in an amount June ¹⁰ CFU / ml the biomass of bacteria of the genus Bifidobacterium (Table 2) selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88 , Bifidobacterium infantis 79-43, Bifidobacterium longum I-3 , Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513, and containing target additives (table 3) in an amount of 0.01 wt.% From the weight of the product, selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, licorice root extract, rosehip extract, oregano extract, cranberry extract and flavor additive. An immunobiological agent was administered orally once a day, for 14 days, in 5 doses (5x10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, pink lichen resolved, exacerbation of chronic pharyngitis stopped within 6 days (previous exacerbations of chronic pharyngitis in the patient lasted for 2-3 weeks). Correction of intestinal microbiocenosis occurred. Streptococcus pyogenes was eliminated. Therefore, it was established the presence of anti-allergic action, anti-infectious action of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis.

Example 24. Patient Z., 40 years old. Diagnosis: pink lichen, chronic pharyngitis in the acute stage, intestinal dysbiosis, carriage of Staphylococcus aureus, inorganic etiology insomnia (psychological adaptation disorder). The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ⁷ CFU / ml, containing filtrate the phagolysate of non-lysogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteus b an acteriophage, Pseudomonas bacteriophage, Salmonella bacteriophage, Shigellosis bacteriophage, Enterococcal bacteriophage and Klebsiella bacteriophage - in the form of virulent bacteriophages and bacteriophages with induced virulence with lytic activity not lower than 10 ^-4 according to Appelman isolate from bacteria in the test strains and concentrate the filtrate fagolizata nelizogennyh bacterial biomass comprising Lactobacillus acidophilus strain K ₃ W ₂₄ in the culture medium in an amount of 10 ⁷ cfu / ml, in a cul medium comprising ivirovaniya in an amount of 10 ⁷ cfu / ml of bacteria biomass genus Bifidobacterium (Table 2) selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88 , Bifidobacterium infantis 79-43, Bifidobacterium longum I-3 , Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513, and containing target additives (table 3) in an amount of 10.0 wt.% By weight of the product selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, licorice root extract, rosehip extract, oregano extract, cranberry extract and flavor additive. An immunobiological agent was administered orally once a day, for 10 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, pink lichen resolved, exacerbation of chronic pharyngitis stopped within 5 days (previous exacerbations of chronic pharyngitis in the patient lasted for 2-3 weeks). Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. The sleep normalized - a stable psycho-emotional state was restored. Therefore, it was found that there is an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis and a disorder of psychological adaptation.

Example 25. Patient T., 22 years old. Diagnosis: atopic dermatitis in the acute stage, chronic tonsillitis in the acute stage, allergic gastroenteritis, intestinal dysbiosis, carriage of Staphylococcus aureus, a disorder of psychological adaptation (in the form of decreased memory and attention functions). The patient was treated with an immunobiological antiallergic agent containing the biomass of the Lactobacillus acidophilus strain 100 ash PA, deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in a culture medium in an amount of 10 ¹⁰ CFU / ml, containing filtrate the phagolysate of non-isogenic bacteria, species-specific bacteriophages (table 1), selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, if bacteriophage, proteinaceous akteriofag, Pseudomonas phage, Salmonella phage, shigellosis bacteriophage, and bacteriophage enterococcal klebsiellezny bacteriophage, - a virulent bacteriophages and bacteriophages with induced virulence with lytic activity of not lower than 10 ^-4 for Appelmanu against the test strains and isolated from the human body in the bacteria isolates concentrate the filtrate fagolizata nelizogennyh bacterial biomass comprising Lactobacillus acidophilus strain K ₃ W ₂₄ in the culture medium in an amount of 10 ¹⁰ pfu / ml, containing molecules in the medium tivirovaniya in an amount of 10 ¹⁰ pfu / ml of biomass of bacteria of Bifidobacterium (Table 2) selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88 , Bifidobacterium infantis 79-43, Bifidobacterium longum I-3 , Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513, and containing target additives (table 3) in an amount of 95.0 wt.% By weight of the product selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan, licorice root extract, rosehip extract, oregano extract, cranberry extract and flavor I am an additive. An immunobiological agent was administered orally once a day, for 14 days, 5 doses (5 × 10 ⁷ CFU) of Lactobacillus acidophilus 100 al PA - the maximum single dose used for intestinal dysbiosis. After the course of treatment, exacerbation of atopic dermatitis was stopped. Exacerbation of chronic tonsillitis was stopped within 3 days (previous exacerbations of chronic pharyngitis in the patient lasted for 10-14 days). Correction of intestinal microbiocenosis occurred. Staphylococcus aureus was eliminated. A stable psycho-emotional state was restored (the functions of memory and attention were restored). Therefore, it was found that there is an anti-allergic effect, an anti-infectious effect of an immunobiological anti-allergic agent containing a strain of Lactobacillus acidophilus 100 al PA, and its effectiveness in intestinal dysbiosis and a disorder of psychological adaptation.

Thus, variants of an immunobiological antiallergic agent containing the Lactobacillus acidophilus 100 ash strain PA deposited in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Medicine named after G.N. Gabrichevsky Rospotrebnadzor under No. 207, in all patients showed anti-allergic effect, which proves the stability of the determined biological properties of the strain Lactobacillus acidophilus 100 ash PA. In addition, the variants of the claimed immunobiological anti-allergic drugs were effective in diseases of infectious etiology, intestinal dysbiosis and a disorder of psychological adaptation.

Given the presence of the Lactobacillus acidophilus 100 ash strain PA anti-allergic properties, as well as the properties of the variants of the immunobiological anti-allergic agent containing it, the claimed strain can be used in the production of medical immunobiological agents, food products and biologically active food additives indicated for the prevention and treatment of allergic or pseudo-allergic diseases without concomitant pathology or in combination with a disease of infectious etiology, intestinal dysbiosis and distress ystvom psychological adaptation.

Table 1 Variants of the composition of bacteriophages of an immunobiological antiallergic agent Bacteriophages Variant of the composition of bacteriophages one 2 3 four 5 6 7 8 9 10 eleven 12 staphylococcal bacteriophage + - - - - - - - - + + + streptococcal bacteriophage - + - - - - - - - - + + if bacteriophage - - + - - - - - - + + + Protein bacteriophage - - - + - - - - - + + + Pseudomonas bacteriophage - - - - + - - - - + + + salmonella bacteriophage - - - - - + - - - + - - shigellosis bacteriophage - - - - - - + - - + - - enterococcal bacteriophage - - - - - - - + - + + - klebsiellosis bacteriophage - - - - - - - - + - + -

table 2 Variants of the composition of bacteria of the genus Bifidobacterium immunobiological antiallergic agents Bifidobacterium bacteria Variant of the composition of bacteria of the genus Bifidobacterium one 2 3 four 5 6 7 8 9 10 eleven 12 13 fourteen Bifidobacterium bifidum 1 + + + + + + + + + + + + - + Bifidobacterium bifidum 791 - + + + + + + + + + + + + + Bifidobacterium longum B379M - - + - - - - + - + + + + + Bifidobacterium breve 79-88 - - - + - - - + + - + + - + Bifidobacterium infantis 79-43 - - - - + - - + + - + + - + Bifidobacterium longum I-3 + + + + + + - - - + + + + + Bifidobacterium adolescentis GO-13 + + + + + + + - - + + - + + Bifidobacterium breve 79-119 + + + + + + + + + - + - - + Bifidobacterium infantis 73-15 + + + + + + + + + - + - - + Bifidobacterium bifidum LVA-3 + + + + + + + + + + + + + + Bifidobacterium adolescentis G7513 + + + + + + + + + + + + + +

Table 3 Variants of the composition of target additives of an immunobiological antiallergic agent in the form of a suspension Targeted Supplements The composition of the target additives one 2 3 four 5 6 7 8 9 10 eleven 12 13 fourteen glycine + + - + + + + - - + + + + + cysteine + - + - - - + + + + - - + + copper sulfate + + + + + - - - + + + - - + copper gluconate - - - - - - - - - + - + + - quinosol + + + - - + + + - + + + + + chitosan + + + - - + - + + + + + + + licorice root extract + - + + - + - + + + + + + + rosehip extract + + + + - + - + + + + + + + oregano extract + + - - - + - + + + + + + + cranberry extract + + + - + + - + + + + + + + flavoring additive + + + - - + - + + + + + + +

Claims (10)

1. An immunobiological antiallergic agent, characterized in that it contains a strain of Lactobacillus acidophilus 100 ash PA, collection No. 207, is stored in the State collection of microorganisms of normal microflora of the Federal State Institution of Medical Sciences named after G.N. Gabrichevsky of Rospotrebnadzor and is used in the prevention and treatment of allergic or pseudo-allergic disease concomitant pathology or in combination with a disease of infectious etiology, intestinal dysbiosis and a disorder of psychological adaptation. 2. An immunobiological antiallergic agent, characterized in that it contains the biomass of the strain Lactobacillus acidophilus 100 ash PA, collection No. 207, is stored in the State collection of microorganisms of normal microflora of the Federal State Medical Research Institute named after G.N. Gabričevsky Rospotrebnadzor, in a culture medium in an amount of 10 ⁶ -10 ¹⁰ CFU / ml and is used in the prevention and treatment of allergic or pseudo-allergic diseases without concomitant pathology or in combination with an infectious etiology disease, intestinal dysbiosis and a disorder of psychological adaptation. 3. An immunobiological anti-allergic agent, characterized in that it contains the biomass of the strain Lactobacillus acidophilus 100 ash PA, collection No. 207, is stored in the State collection of microorganisms of normal microflora of the Federal State Institution of Medicine and Science named after G.N. Gabrichevsky Rospotrebnadzor, in a culture medium in an amount of 10 ⁶ -10 ¹⁰ CFU / ml, and desired additives, and is used in the prevention and treatment of allergic diseases or pseudoallergic without concomitant pathologies or in combination with an infectious disease etiology disbakte iozom bowel disorder and psychological adaptation. 4. The immunobiological antiallergic agent according to claim 3, characterized in that it contains targeted additives selected from the series: species-specific bacteriophages with lytic activity not lower than 10 ^-4 according to Appelman in relation to test strains and bacterial isolates isolated from the human body in the concentrate filtrate fagolizata nelizogennyh bacterial biomass of the strain Lactobacillus acidophilus K ₃ W ₂₄ in the culture medium in an amount of 10 ⁶ -10 ¹⁰ cfu / ml, the biomass of the strain Lactobacillus acidophilus NK ₁ in the culture medium in an amount of 10 ⁶ -10 ¹⁰ CFU / ml bacteria and biomass ode Bifidobacterium in the medium in an amount of 10 ⁶ -10 ¹⁰ CFU / ml. 5. The immunobiological anti-allergic agent according to claim 4, characterized in that it contains species-specific virulent bacteriophages selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, coli bacteriophage, proteus bacteriophage, Pseudomonas bacteriophage, salmonella bacteriophage, shigellosis and gellogiosis phagellosis phagellosis . 6. The immunobiological anti-allergic agent according to claim 4, characterized in that it contains species-specific virulent bacteriophages and bacteriophages with induced virulence, selected from the series: staphylococcal bacteriophage, streptococcal bacteriophage, coli bacteriophage, proteus bacteriophage, Pseudomonas bacteriophages, bacteriophage phage, enterococcal bacteriophage and Klebsiella bacteriophage. 7. The immunobiological anti-allergic agent according to claim 4, characterized in that it contains bacteria of the genus Bifidobacterium, selected from the series: Bifidobacterium bifidum 1, Bifidobacterium bifidum 791, Bifidobacterium longum B379M, Bifidobacterium breve 79-88, Bifidobacterium breve 79-88, Bifidobacterium breve 79-88, Bifidobacterium breve 79-88, bifidobacterium breve 79-88, infant I-3, Bifidobacterium adolescentis GO-13, Bifidobacterium breve 79-119, Bifidobacterium infantis 73-15, Bifidobacterium bifidum LVA-3 and Bifidobacterium adolescentis G7513. 8. The immunobiological anti-allergic agent according to claim 3, characterized in that it additionally contains target additives in an amount of 0.01-95.0% by weight of the agent selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosol, chitosan , licorice root extract, rosehip extract, oregano extract, cranberry extract and flavoring additive and is presented in the form of a suspension. 9. The immunobiological anti-allergic agent according to claim 4, characterized in that it additionally contains target additives in an amount of 0.01-95.0% by weight of the agent selected from the series: glycine, cysteine, copper sulfate, copper gluconate, chinosole, chitosan , licorice root extract, rosehip extract, oregano extract, cranberry extract and flavoring additive and is presented in the form of a suspension. 10. The strain Lactobacillus acidophilus 100 ash PA, collection No. 207, is stored in the State collection of microorganisms of normal microflora of the Federal State Institution of Medical Sciences named after G.N.